At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 99 enrolled
Drug / intervention
AZD2014 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I, Open-label, Multicentre, Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD2014 Administered Orally in Combination With Intramuscular (IM) Fulvestrant to Patients With Estrogen Receptor Positive (ER+) Advanced, Metastatic Breast Cancer
In Brief
A Phase 1 clinical trial evaluating AZD2014 and Fulvestrant for Advanced Metastatic Breast Cancer. Completed, enrolled 99 participants across 5 sites.
Detailed Summary
The purpose of this study is to assess safety and tolerability of AZD2014 when given in combination with Fulvestrant
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Metastatic Breast Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2012
First PostedMay 2012
Primary CompletionAug 2016
Study CompletionJan 2026
TodayJul 2026
First PostedMay 14, 2012
Enrollment StartMay 8, 2012
Primary CompletionAug 4, 2016
Study CompletionJan 13, 2026
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 14.1 years ago
Interventions
AZD2014drug
Single dose followed by multiple dosing or twice daily dosing for 2 days folllowed by 5 days off each week, or twice daily dosing on the first and fourth day of the week
Fulvestrantdrug
IM monthly after loading dose